As investigated by Wang et al., patients with high expression of apurinic/apyrimidinic endonuclease 1 (APE1) and therefore to cisplatin were only included for examination of the AT-101 and cisplatin regimen in a cohort of advanced non-small cell lung cancer [96]. Here, APEX1 is linked to non-small cell lung carcinoma.